UNITED THERAPEUTICS ($UTHR) posted quarterly earnings results for Q2 2026 on Wednesday, August 5th. The company reported earnings of $7.27 per share, beating estimates of $6.97 by $0.30. The company also reported revenue of $783,300,000, missing estimates of $821,758,369 by $-38,458,369.
You can see Quiver Quantitative's $UTHR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
UNITED THERAPEUTICS Insider Trading Activity
UNITED THERAPEUTICS insiders have traded $UTHR stock on the open market 1373 times in the past 6 months. Of those trades, 0 have been purchases and 1373 have been sales.
Here’s a breakdown of recent trading of $UTHR stock by insiders over the last 6 months:
- MARTINE A ROTHBLATT (Chairperson & CEO) has made 0 purchases and 994 sales selling 902,575 shares for an estimated $492,877,620.
- JAMES EDGEMOND (CFO AND TREASURER) has made 0 purchases and 272 sales selling 238,750 shares for an estimated $134,032,698.
- PAUL A MAHON (EVP & GENERAL COUNSEL) has made 0 purchases and 85 sales selling 83,000 shares for an estimated $44,853,247.
- MICHAEL BENKOWITZ (PRESIDENT AND COO) has made 0 purchases and 4 sales selling 36,940 shares for an estimated $17,497,185.
- RAY KURZWEIL sold 4,910 shares for an estimated $2,401,088
- CHRISTOPHER PATUSKY has made 0 purchases and 2 sales selling 3,910 shares for an estimated $2,234,670.
- TOMMY G THOMPSON has made 0 purchases and 4 sales selling 4,000 shares for an estimated $2,057,171.
- CHRISTOPHER CAUSEY has made 0 purchases and 3 sales selling 2,320 shares for an estimated $1,315,835.
- JUDY D. OLIAN has made 0 purchases and 4 sales selling 800 shares for an estimated $416,998.
- JAN MALCOLM has made 0 purchases and 3 sales selling 420 shares for an estimated $226,683.
- NILDA MESA sold 258 shares for an estimated $150,139
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
UNITED THERAPEUTICS Hedge Fund Activity
We have seen 369 institutional investors add shares of UNITED THERAPEUTICS stock to their portfolio, and 394 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AQR CAPITAL MANAGEMENT LLC removed 455,473 shares (-35.5%) from their portfolio in Q1 2026, for an estimated $265,627,298
- BLACKROCK, INC. added 228,883 shares (+4.4%) to their portfolio in Q1 2026, for an estimated $133,482,276
- JANE STREET GROUP, LLC removed 214,061 shares (-98.7%) from their portfolio in Q1 2026, for an estimated $124,838,234
- WELLINGTON MANAGEMENT GROUP LLP removed 177,245 shares (-7.3%) from their portfolio in Q1 2026, for an estimated $103,367,511
- CITADEL ADVISORS LLC added 173,479 shares (+92.7%) to their portfolio in Q1 2026, for an estimated $101,171,218
- FIFTH THIRD BANCORP added 164,519 shares (+35842.9%) to their portfolio in Q1 2026, for an estimated $95,945,835
- WICK CAPITAL PARTNERS, LLC removed 155,259 shares (-99.7%) from their portfolio in Q1 2026, for an estimated $90,545,496
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
UNITED THERAPEUTICS Government Contracts
We have seen $1,691,396 of award payments to $UTHR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TYVASO KITS & CARTRIDGES: $379,307
- PATIENT MEDICATION OF TYVASO 80MG - SHIPPING TO THE BALTIMORE VA MEDICAL CENTER PHARMACY.: $33,158
- TYVASO 80 MCG: $33,158
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
UNITED THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $UTHR recently. We have seen 9 analysts offer price targets for $UTHR in the last 6 months, with a median target of $660.0.
Here are some recent targets:
- Lisa Walter from RBC Capital set a target price of $704.0 on 07/07/2026
- Benjamin Burnett from Wells Fargo set a target price of $738.0 on 05/07/2026
- Terence Flynn from Morgan Stanley set a target price of $519.0 on 04/10/2026
- Greg Harrison from B of A Securities set a target price of $626.0 on 03/31/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $660.0 on 03/31/2026
- Joseph Thome from TD Cowen set a target price of $660.0 on 03/30/2026
- Olivia Brayer Saunders from Cantor Fitzgerald set a target price of $625.0 on 03/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
